BCI Sector Macro

Thesis

The brain-computer interface sector experienced a step-change in institutional interest in 2025, with total funding tripling to $867M. This represents a shift from BCI being viewed as a science fiction concept to an investable technology category with multiple companies approaching clinical validation. The three most prominent players. Neuralink (direct cortical, Musk-backed), Synchron (endovascular, Gates/Bezos-backed), and Paradromics (high-bandwidth, 200+ bps record). Represent distinct technical approaches, creating a portfolio of bets across the solution space. The sector's investability is constrained by the private nature of all major players. Synchron and Neuralink may have secondary market shares available on platforms like Forge Global and EquityZen for accredited investors, but liquidity is extremely limited. No public equity or digital asset provides pure BCI exposure. The sector is best positioned as a thematic allocation within a broader frontier technology portfolio. Key macro catalysts include expanding FDA pathways for BCI devices, growing evidence from clinical trials demonstrating safety and efficacy, and increasing public acceptance of neural interface technology. The $867M funding figure in 2025 alone suggests institutional capital sees a path to commercial returns, even though the timeline to widespread adoption remains uncertain. Risks include regulatory setbacks, ethical backlash against brain implants, and the possibility that non-invasive approaches (EEG-based) may prove sufficient for many use cases.

Catalysts

• +BCI funding tripled to $867M in 2025. Institutional capital entering at scale
• +Multiple FDA-authorized clinical trials generating safety and efficacy data
• +Three distinct technical approaches (endovascular, cortical, high-bandwidth) de-risk the sector as a whole

Risks

• -All major BCI companies are private. No pure public market exposure available
• -Regulatory and ethical scrutiny could slow clinical timelines or impose restrictive conditions
• -Non-invasive approaches (EEG-based BCI) may prove sufficient for many use cases, limiting addressable market for invasive devices

Common questions